Obesity Management Market Key Developments 2019: GlaxoSmithKline Plc., VIVUS, Inc., Novo Nordisk A/S, Arena Pharmaceuticals, Inc.
High costs involved in the research & development (R&D) of obesity drugs, coupled with limited financial support, are collectively a great challenge for adoption of obesity management solutions. Additionally, long gestation time needed for R&D activities, and the inclusion of clinical trials required to test these drugs hikes the expenditure significantly. Considering this scenario, manufacturers are being cautious while seeking better return on investments. In the long run, risks and limitations posed by the high development costs of obesity drugs...
View full press release